Filing Details
- Accession Number:
- 0000905148-21-000408
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-04-29 18:44:07
- Reporting Period:
- 2021-04-27
- Accepted Time:
- 2021-04-29 18:44:07
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1445499 | Impel Neuropharma Inc | IMPL | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1278411 | S Corey Goodman | 1700 Owens Street Suite 595 San Francisco CA 94158 | No | No | No | No | |
| 1329161 | J Robert Adelman | 1700 Owens Street Suite 595 San Francisco CA 94158 | No | No | No | No | |
| 1634632 | L.p. Ii Fund Strategic Global Venbio | 1700 Owens Street Suite 595 San Francisco CA 94158 | No | No | No | No | |
| 1729408 | Venbio Global Strategic Gp Ii, Ltd. | 1700 Owens Street Suite 595 San Francisco CA 94158 | No | No | No | No | |
| 1729409 | Venbio Global Strategic Gp Ii, L.p. | 1700 Owens Street Suite 595 San Francisco CA 94158 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-04-27 | 2,309,791 | $0.00 | 2,309,791 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2021-04-27 | 450,000 | $15.00 | 2,759,791 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Direct | |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series D Redeemable Convertible Preferred Stock | Disposition | 2021-04-27 | 5,876,034 | $0.00 | 358,878 | $0.00 |
| Common Stock | Series C-3 Redeemable Convertible Preferred Stock | Disposition | 2021-04-27 | 8,201,930 | $0.00 | 500,932 | $0.00 |
| Common Stock | Series C-2 Redeemable Convertible Preferred Stock | Disposition | 2021-04-27 | 8,845,942 | $0.00 | 540,265 | $0.00 |
| Common Stock | Series C-1 Redeemable Convertible Preferred Stock | Disposition | 2021-04-27 | 13,233,885 | $0.00 | 808,259 | $0.00 |
| Common Stock | 5% Convertible Note due 2021 | Disposition | 2021-04-27 | 0 | $0.00 | 101,457 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct | ||
| 0 | 2021-12-31 | No | 4 | C | Direct |
Footnotes
- These shares of the issuer's Series D redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's initial public offering ("IPO"), and had no expiration date.
- These shares of the issuer's Series C-3 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date.
- These shares of the issuer's Series C-2 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date.
- These shares of the issuer's Series C-1 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date.
- This convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest automatically converted into the number of shares of the issuer's common stock shown in Column 7 upon the closing of the issuer's IPO at $13.50 per share (90% of the IPO price).
- The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein.
Billionaire Hedge Funds
